Clinical Trials on Malignant Extragonadal Germ Cell Tumor

Total 10235 results

Hoffmann-La Roche

Completed

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

Malignant Melanoma

Switzerland
Oslo University Hospital

Active, not recruiting

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (Ipi4)

Malignant Melanoma

Norway
Ultimovacs ASA

Active, not recruiting

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Malignant Melanoma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

Malignant Melanoma

United States
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
Bristol-Myers Squibb
Medarex; Ono Pharma USA Inc

Completed

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Medical University of Graz

Completed

Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma

Malignant Melanoma

Austria
Prof. Dr. med. Dirk Schadendorf

Terminated

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma (BOTTOM)

Malignant Melanoma

Germany
Immunocore Ltd

Terminated

IMCgp100-401 Rollover Study

Malignant Melanoma

United States, United Kingdom
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
Immunocore Ltd

Completed

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Malignant Melanoma

United Kingdom, United States
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Hoffmann-La Roche

Completed

A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Malignant Melanoma

China
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Malignant Melanoma

Italy
Hadassah Medical Organization

Unknown

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Malignant Melanoma

Israel
Merck Sharp & Dohme LLC

Terminated

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

Malignant Melanoma
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
Celgene
NYU Langone Health; Syneos Health; Celerion; ApoCell, Inc.

Completed

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Malignant Melanoma

United States
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Malignant Melanoma

United States
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
H. Lee Moffitt Cancer Center and Research Institute
National Gene Vector Laboratory

Completed

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

Malignant Melanoma

United States
Genentech, Inc.

Completed

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Malignant Melanoma

United States, Australia
Hoffmann-La Roche

Terminated

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Malignant Melanoma

United States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia
Oslo University Hospital

Completed

Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma

Malignant Melanoma

Norway
James Graham Brown Cancer Center
University of Louisville

Completed

Phase II Trial of Ontak With Metastatic Melanoma

Malignant Melanoma

United States
Yonsei University

Completed

A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy

Malignant Melanoma

Korea, Republic of
SciBase AB

Completed

SciBase International Melanoma Pivotal Study

Malignant Melanoma

United States, Sweden
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
AmpliMed Corporation

Completed

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Malignant Melanoma

United States
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center

Completed

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

Malignant Melanoma

United States
NeoPlas Innovation

Withdrawn

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Melanoma | Malignant Melanoma

United States
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
Northern California Melanoma Center
Bayer; Melanoma Research Institute

Completed

GM-CSF as Adjuvant Therapy of Melanoma

Malignant Melanoma

United States
Titan Pharmaceuticals

Terminated

A Pilot Study of Pivanex in Patients With Malignant Melanoma

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin

Testicular Germ Cell Tumor | Ovarian Cancer

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
University of Iowa
Novartis

Not yet recruiting

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)

Neuroendocrine Tumors | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
CNAO National Center of Oncological Hadrontherapy

Recruiting

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract (CYCLE)

Gynecologic Cancer | Malignant Melanoma

Italy
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
University Hospital Tuebingen

Unknown

Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI

Malignant Melanoma Stage IV

Germany
University Medical Center Groningen

Completed

DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor

Neuroendocrine Tumor

Netherlands
University Medical Center Groningen

Completed

Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study (VIDEO-NET)

Neuroendocrine Tumor

Netherlands
Novartis Pharmaceuticals

Completed

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Neuroendocrine Tumor

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Unknown

Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors

Neuroendocrine Tumor

United States
Hadassah Medical Organization

Unknown

Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors

Neuroendocrine Tumor

Israel
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Malignant Brain Tumor

United States
Wren Laboratories LLC

Active, not recruiting

Surgical Intervention and the NETest (NETest_Sx)

Neuroendocrine Tumor | Gastroenteropancreatic

Italy
Universitaire Ziekenhuizen KU Leuven

Terminated

18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors

Neuroendocrine Tumors | Neural Crest Tumor

Belgium
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

Extrapancreatic Neuroendocrine Tumor

China

Clinical Trials on Malignant Extragonadal Germ Cell Tumor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations